Floatz logo

Therapeutic Asset Ratings

440 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Rucaparib
Ovarian Cancer
pharmaand GmbHP3B (61)
Calcium folinate pentahydrate
Ovarian Cancer
Lipomedix Pharmaceuticals Inc.P2B (61)
Sargramostim
Ovarian Cancer
Aston Sci. Inc.P2B (61)
Acetylsalicylic Acid
Ovarian Cancer
H. Lee Moffitt Cancer Center and Research InstituteP4B (60)
Fluzoparib
Ovarian Cancer
Shandong UniversityP3B (60)
Lurbinectedin
Ovarian Cancer
M.D. Anderson Cancer CenterP3B (60)
Pembrolizumab
Ovarian Cancer
Kalinski, Pawel, MD, PhDP3B (60)
Veliparib
Ovarian Cancer
AbbVieP3B (60)
Nivolumab
Ovarian Cancer
Regeneron PharmaceuticalsP2B (60)
Eloxatin
Ovarian Cancer
Qilu Pharmaceutical Co., Ltd.P3B (59)
ETOPOSIDE
Ovarian Cancer
Fudan UniversityP3B (59)
Fludarabine
Ovarian Cancer
Zelluna Immunotherapy ASP3B (59)
Capecitabine
Ovarian Cancer
OHSU Knight Cancer InstituteP3B (58)
Chiauranib
Ovarian Cancer
Chipscreen Biosciences, Ltd.P3B (58)
Durvalumab
Ovarian Cancer
British Columbia Cancer AgencyP3B (58)
Famitinib
Ovarian Cancer
Jinhua ZhouP3B (58)
hs-20089
Ovarian Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P3B (58)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Ovarian Cancer
OHSU Knight Cancer InstituteP3B (58)
Letrozole
Ovarian Cancer
Peking Union Medical College HospitalP3B (58)
Pamiparib
Ovarian Cancer
Sun Yat-sen UniversityP3B (58)
TAMOXIFEN
Ovarian Cancer
OHSU Knight Cancer InstituteP3B (58)
Trastuzumab Deruxtecan
Ovarian Cancer
Yonsei UniversityP3B (58)
Vinorelbine
Ovarian Cancer
OHSU Knight Cancer InstituteP3B (58)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ovarian Cancer
AstraZenecaP2B (58)
Gm-Csf
Ovarian Cancer
Georgetown UniversityP2B (58)
Showing 26 to 50 of 440 assets
PreviousPage 2 of 18Next